Yarrow Bioscience Reports Q2 2026 Financial Results and Provides Pre‑Merger Financials

What Happened

• On August 13, 2026, Yarrow Bioscience (YARW) filed Amendment No. 1 to its Form 8-K to provide additional financial disclosures under Item 2.02. The amendment supplies Pre‑Merger Yarrow’s financial statements and Management’s Discussion & Analysis (MD&A) for the three- and six-month periods ended June 30, 2026, as well as financials as of December 31, 2025 and October 3, 2025 (the company’s inception) that were recast to give retroactive effect to the Exchange Ratio. The filing also includes unaudited pro forma condensed combined balance sheet as of June 30, 2026 and unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2026 and the year ended December 31, 2025. A press release with the quarter‑end results and an updated corporate presentation were furnished as exhibits.

Key Details

• Filing date: August 13, 2026 (Amendment No. 1 to Form 8-K).
• Financials provided: Pre‑Merger Yarrow statements for the three- and six-month periods ended June 30, 2026 and for periods ending Dec 31, 2025 and Oct 3, 2025 (inception), recast for the Exchange Ratio.
• Pro forma statements: Unaudited pro forma condensed combined balance sheet as of June 30, 2026 and pro forma statements of operations for the six months ended June 30, 2026 and year ended Dec 31, 2025.
• Exhibits: MD&A attached as Exhibit 99.5; press release for Q2 2026 results as Exhibit 99.7; updated corporate presentation as Exhibit 99.8.

Why It Matters

• Investors now have the underlying Pre‑Merger financials and management discussion that support the company’s reported Q2 2026 results and allow assessment of the combined company’s financial position. The recast financials reflecting the Exchange Ratio and the unaudited pro forma statements are important for understanding how the merger/exchange affects historical comparatives, balance sheet composition, and operating results. The MD&A and updated corporate presentation provide management context for the quarter and any strategic updates.